Cephalon Inc. said this week that an anxiety disorder drug candidate it has been working on failed to meet the goals of a late-stage study.
Gabitril, as the drug is known, is currently used in Europe and America to treat partial seizures in children 12 and over. The company did not elaborate on the study results, but said the data are being analyzed to determine future development plans in other areas.
The drug had been part of a series of studies to determine its efficacy in treating anxiety disorders such as Generalized anxiety disorder, or GAD. Gabitril is a selective GABA-reuptake inhibitor (SGRI), which selectively inhibits the reuptake of gamma aminobutyric acid, or GABA, and thus increases the levels of synaptic GABA. Abnormalities in GABA neurotransmission have been linked to a variety of disorders, including epilepsy and anxiety.
© Copyright 2007 Insight Journal Online Magazine.
Join the Discussion:
Discuss and ask questions in our community forums
Recommended Links:
Sign up for our FREE Health and Wellness Newsletter
View More Articles In
Category: Drug and Product Watch
Digg
Stumble It!
del.icio.us
Add to Any
